Open AccessProphylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)–Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection
Author(s) -
Katherine V. Houser,
Lisa Gretebeck,
Tianlei Ying,
Yanping Wang,
Leatrice Vogel,
Elaine W. Lamirande,
Kevin W. Bock,
Ian N. Moore,
Dimiter S. Dimitrov,
Kanta Subbarao
Publication year - 2016
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiw080
Subject(s) - middle east respiratory syndrome coronavirus , virology , middle east respiratory syndrome , covid-19 , monoclonal antibody , coronavirus , coronavirus infections , betacoronavirus , medicine , antibody , immunology , biology , outbreak , pathology , infectious disease (medical specialty) , disease
With >1600 documented human infections with Middle East respiratory syndrome coronavirus (MERS-CoV) and a case fatality rate of approximately 36%, medical countermeasures are needed to prevent and limit the disease. We examined the in vivo efficacy of the human monoclonal antibody m336, which has high neutralizing activity against MERS-CoV in vitro. m336 was administered to rabbits intravenously or intranasally before infection with MERS-CoV. Prophylaxis with m336 resulted in a reduction of pulmonary viral RNA titers by 40-9000-fold, compared with an irrelevant control antibody with little to no inflammation or viral antigen detected. This protection in rabbits supports further clinical development of m336.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom